ArticleJournal of medical case reports2026
Immunotherapy-based neoadjuvant treatment of gastric cancer with elevated serum AFP: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAlpha-fetoprotein-producing gastric cancer (AFPGC) is a rare type of gastric cancer with a high degree of malignancy and a poor prognosis. The standardized treatment process for this type of gastric cancer has not yet been defined, and the available treatment options are limited. However, with the development of molecular biology and immunology, more therapeutic options are available for gastric cancer patients. Immunotherapy has made substantial progress in the treatment of many solid tumors, but there are rare reports on the therapeutic efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with AFPGC. CASE PRESENTATION: We conducted a retrospective analysis of six Asian patients with AFPGC, among them were four males and two females, aged 61, 66, 63, 72, 70, and 72 years, respectively, all of whom were Asian. Five of the patients achieved pathologic complete response (pCR) and one patient pathologic partial remission by combining chemotherapy and immunotherapy, and no recurrence was observed during postoperative follow-up. Moreover, the treatment was well tolerated and the quality of life of the patients was assured during the treatment period.
conclusionsWe report six cases of locally advanced, non-metastatic gastric cancer with elevated AFP, all of which demonstrated a favorable response and were well tolerated by the patients after the use of immune checkpoint inhibitors and neoadjuvant chemotherapy. This study suggests that programmed death receptor 1(PD-1) checkpoint inhibitors plus chemotherapy can benefit patients with AFPGC and provide a reference for the treatment of patients with AFPGC, and its mechanism of action deserves further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.